[Therapeutic effect of human immunoglobulin, SM-4300, against severe respiratory tract infections].
SM-4300, a newly developed human immunoglobulin for intravenous use, has been studied for the safety and effectiveness/efficacy in the 7 patients with severe respiratory infections and a patient with fever of undetermined origin. Severe infections in the patients considered of 3 cases of pneumonia, 2 of obstructive pneumonia due to lung cancer, 2 of diffuse panbronchiolitis and 1 of fever of undetermined origin. Clinical effects of SM-4300 were excellent in 1 case, good in 1, fair in 2 and poor in 4. The efficacy rate was 25.0%. The appearance of subjective and objective clinical side effects and abnormal laboratory findings related to SM-4300 administration were not noted.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001419:Bacteria / Q000276:immunology; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000628:therapy*
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300